T
Tetherex Pharmaceuticals
Tetherex Pharmaceuticals operates in the healthcare industry focusing on biotechnology business
About Tetherex Pharmaceuticals
Tetherex Pharmaceuticals is a biopharmaceutical startup that operates in the healthcare sector, specifically focusing on the research and development of treatments for inflammatory and infectious diseases, as well as cancer. The company's primary clientele includes patients suffering from these afflictions, with the ultimate goal of enhancing their quality and longevity of life.
Tetherex's business model revolves around the advancement of scientific understanding of inflammation in various disease processes. The company invests heavily in medical research, with a particular emphasis on the molecular mechanisms of inflammation. This research has led to the development of innovative therapeutic candidates for inflammatory diseases, positioning Tetherex as a leader in this niche market.
The company generates revenue through the development and commercialization of these novel products. This involves extensive research and development, followed by clinical trials, regulatory approval, and finally, the marketing and sale of these products to healthcare providers.
Tetherex prides itself on its commitment to integrity and excellence in medical research, with its employees dedicated to advancing the understanding and treatment of these diseases. This commitment is reflected in the company's pioneering work and breakthroughs in the field of inflammation and disease treatment.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2014
- Headquarters
- Oklahoma City, United States
- Employees
- 4
- Open positions
- None listed
- Dealroom signal
- 55.2/100
- Industry
- Health
- Sub-industry
- Pharmaceutical
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, Longevity, DT and LS, science-based
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Apr 2018 | $50M | $200M | MPM BioImpact | — |
| DEBTDebt | Jun 2015 | $2M | — | Undisclosed | — |
Growth signals
Latest recorded traffic for Tetherex Pharmaceuticals is 610 monthly website visits, up 154.2% over the last three months. Tetherex Pharmaceuticals's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
I2E
Series A1 investor entered at this stage
MPM BioImpact
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Tetherex Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Tetherex Pharmaceuticals’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.